Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017
Added 4 months ago Drug news
Zoptrex (zoptarelin doxorubicin) fails to meet primary endpoint in endometrial cancer- Aeterna Zentaris
Aeterna Zentaris announced that the ZoptEC Phase III clinical study of Zoptrex (zoptarelin doxorubicin) in women with locally advanced, recurrent...
Added 4 years ago Drug news
The FDA has approved an upcoming Phase III registration trial in Endometrial Cancer for AEZS-108 from Aeterna Zentaris Inc. This...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
This document is intended to fulfil several objectives: - To promote a uniformly high standard of care for women with...
Added 3 years ago
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Olaparib is the first oral poly(ADP-ribose) polymerase inhibitor to be approved as maintenance monotherapy for treatment of patients with platinum-sensitive relapsed BRCA-mutated (BRCAm) serous ovarian cancer.
Added 5 months ago
Introduction: Despite recent advances in the management of epithelial ovarian cancer, overall survival rates remain poor, and there is a pressing need to develop novel therapeutic agents and maintenance strategies ...
Added 1 year ago
Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Background: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about...
Added 2 years ago
PH3 Study of IMGN853 vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer (FORWARD I)
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of IMGN853 to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced...
Added 5 months ago
Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more
Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.